NCT07882758Not yet recruiting
Union-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance
Union-LC-MPE Cohort:A Multicenter Cohort Study on the Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cancer Based on Integrated Clinical, Radiological, and Pleural Fluid Multi-Omics Data
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Lung cancer is the malignant tumor with the highest incidence and mortality rates in China. Malignant pleural effusion (MPE) is one of its most common complications, affecting approximately 15%-50% of patients with non-small cell lung cancer at initial diagnosis or during disease progression and indicating advanced-stage disease with a median survival of only 3-12 months. This study aims to establish the first large-scale, multicenter LC-MPE disease-specific cohort, integrating clinical, imaging, pleural fluid laboratory, pathological and genomic multimodal data to develop an AI-assisted model for the differential diagnosis of benign versus malignant MPE and a prognostic prediction model for LC-MPE patients. The study comprises a retrospective phase (3,000 patients diagnosed between January 2022 and September 2026) and a prospective phase (200 patients diagnosed between October 2026 and October 2028). The primary endpoint is overall survival (OS); secondary endpoints include pleural effusion progression-free survival (PE-PFS), duration of pleural effusion control, and 60-day and 30-day MPE recurrence rates. This observational study does not interfere with routine clinical care and strictly protects the personal information of participants.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 13 Oct 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Lung cancer
- NCT number
- NCT07882758
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 1 Oct 2026 to the primary completion date, 1 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent presence of other primary malignant tumors.
Other illness
- Pleural effusion caused by secondary lung cancer (metastasis to the lung from tumors at other sites).
- Death within 30 days after diagnosis of malignant pleural effusion.
- Mental disorders that prevent cooperation with follow-up.
Lab values
- Severe lack of critical clinical, imaging, or laboratory data.
Who the study is looking for
- Age 18 years or older; gender not restricted.
- Malignant pleural effusion of lung cancer origin.
- Diagnosis confirmed by positive pleural fluid cytology, pleural biopsy, or clinical/imaging comprehensive assessment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.